irinotecan / P53 Cancer Research Results

CPT-11, irinotecan: Click to Expand ⟱
Features:
Irinotecan is a chemotherapy drug widely used to treat several solid tumors. It is a semisynthetic camptothecin derivative and functions primarily as a topoisomerase I inhibitor.
-Active metabolite: SN-38 (much more potent than irinotecan itself)

Common Regimens
Regimen Components
FOLFIRI Folinic acid + 5-FU + Irinotecan
FOLFIRINOX 5-FU + Leucovorin + Irinotecan + Oxaliplatin
XELIRI / CAPIRI Capecitabine + Irinotecan

Potential strategies to sensitize tumors to irinotecan:
Strategy	       Rationale
GSH depletion	       Reduces detox of SN-38
PRDX/TXNRD stress	Lowers redox buffering
Glycolysis inhibition	Limits repair energy
PEMF / AgNPs	        ↑ ROS, ↑ drug uptake
Timing selenium	        Avoid boosting antioxidant defenses during therapy
Report of combining CPT-11 and SeNPs to increase NRF2 in normal cells(chemoprotective) and decrease NRF2 in cancer cells(chemosentization).
P53, P53-Guardian of the Genome: Click to Expand ⟱
Source: TCGA
Type: Proapototic
TP53 is the most commonly mutated gene in human cancer. TP53 is a gene that encodes for the p53 tumor suppressor protein ; TP73 (Chr.1p36.33) and TP63 (Chr.3q28) genes that encode transcription factors p73 and p63, respectively, are TP53 homologous structures.
p53 is a crucial tumor suppressor protein that plays a significant role in regulating the cell cycle, maintaining genomic stability, and preventing tumor formation. It is often referred to as the "guardian of the genome" due to its role in protecting cells from DNA damage and stress.
TP53 gene, which encodes the p53 protein, is one of the most frequently mutated genes in human cancers.
Overexpression of MDM2, an inhibitor of p53, can lead to decreased p53 activity even in the presence of wild-type p53.
In some cancers, particularly those with mutant p53, there may be an overexpression of the p53 protein.
Cancers with overexpression: Breast, lung, colorectal, overian, head and neck, Esophageal, bladder, pancreatic, and liver.
Scientific Papers found: Click to Expand⟱
4734- SeNPs,  CPT-11,    Cytotoxicity and therapeutic effect of irinotecan combined with selenium nanoparticles
- in-vitro, CRC, HCT8 - in-vivo, NA, NA
chemoP↑, ChemoSen↑, P53↑, Apoptosis↑, TumCG↓, Casp↑, Dose↝, NRF2↓, selectivity↑, *NRF2↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

NRF2↓, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   Casp↑, 1,  

DNA Damage & Repair ⓘ

P53↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

TumCG↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   Dose↝, 1,   selectivity↑, 1,  

Functional Outcomes ⓘ

chemoP↑, 1,  
Total Targets: 9

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

NRF2↑, 1,  
Total Targets: 1

Scientific Paper Hit Count for: P53, P53-Guardian of the Genome
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:380  Target#:236  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page